Creative Biolabs, a leading biotechnology research service provider, has announced the expansion of its complement assay service portfolio. This move aims to assist pharmaceutical and biotechnology companies in accelerating the development of next-generation complement therapeutics. The enhanced services offer reliable analytical solutions for evaluating complement pathway activity, therapeutic mechanisms, and candidate performance during preclinical development, addressing a growing need in the field.
The growing interest in complement-targeted drug discovery has increased the demand for specialized functional assays. Researchers developing complement therapeutics often encounter challenges related to complex biological pathways, assay optimization, target validation, and the necessity for reproducible data to guide development decisions. Without robust evaluation methods, identifying promising candidates and understanding their biological effects can become time-consuming and resource-intensive.
Creative Biolabs now offers customizable complement assay solutions for research programs spanning early discovery and preclinical evaluation. Among these offerings is the C3b deposition assay service, which provides a powerful approach for analyzing complement activation by measuring C3b deposition, a critical marker within the complement cascade. This assay supports the characterization of complement-targeting antibodies, proteins, and other therapeutic candidates by providing quantitative data related to pathway regulation and biological activity.
Additionally, the company provides a hemolytic inhibition assay to evaluate the ability of test candidates to inhibit complement-mediated cell lysis. By assessing functional complement inhibition, this assay can support comparisons of candidate inhibitory activity under defined experimental conditions. Furthermore, the company’s individual components activity test services enable detailed analysis of specific complement proteins, supporting mechanism studies and pathway investigations. These capabilities allow researchers to evaluate individual complement components and generate data for mechanistic studies, pathway investigations, and the development of complement-modulating strategies.
The expansion of Creative Biolabs’ complement assay services reflects the company’s continued commitment to supporting complement-focused research. By combining scientific expertise with customized assay solutions, Creative Biolabs aims to help researchers generate actionable data for therapeutic candidate characterization and optimization. With extensive expertise in biotechnology research and assay development, the company delivers flexible and reliable testing solutions that help reduce research complexity and improve development efficiency.
This service expansion is particularly significant given the increasing number of complement-targeted therapies in development for diseases such as autoimmune disorders, inflammatory conditions, and cancer. The availability of robust functional assays is critical for advancing these therapies from bench to bedside. Creative Biolabs’ expanded portfolio provides researchers with the tools necessary to better understand complement biology and evaluate the efficacy of potential therapeutics, ultimately supporting the development of novel treatments that could address significant unmet medical needs.
Researchers and biotechnology organizations seeking reliable complement testing solutions can explore Creative Biolabs’ advanced assay services at https://www.creative-biolabs.com/complement-therapeutics/.
